share_log

康希諾生物：海外監管公告

CANSINOBIO: An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section

Hong Kong Stock Exchange ·  Apr 30 09:06
Summary by Moomoo AI
康希諾生物於2024年4月30日發布公告，披露了2023年度的財務狀況及其他相關信息。公司2023年度報告顯示，年末貨幣資金及交易性金融資產合計約41.30億元，短期借款及長期借款合計約19.20億元。此外，公司期末衍生金融資產129.51萬元，衍生金融負債97.32萬元。公司主要有息負債包括短期及中長期借款，用於日常經營和研發項目，平均融資成本約為2.92%。公司財務收益合計約1.64億元，加權平均收益率約3.3%，符合市場利率水平。康希諾亦開展外匯套期保值業務，以管理金融資產的匯率風險，截至年末，套期保值業務期末賬面凈值32.19萬元，報告期內實現收益1,569.10萬元。公司應收賬款結構...展開全部
康希諾生物於2024年4月30日發布公告，披露了2023年度的財務狀況及其他相關信息。公司2023年度報告顯示，年末貨幣資金及交易性金融資產合計約41.30億元，短期借款及長期借款合計約19.20億元。此外，公司期末衍生金融資產129.51萬元，衍生金融負債97.32萬元。公司主要有息負債包括短期及中長期借款，用於日常經營和研發項目，平均融資成本約為2.92%。公司財務收益合計約1.64億元，加權平均收益率約3.3%，符合市場利率水平。康希諾亦開展外匯套期保值業務，以管理金融資產的匯率風險，截至年末，套期保值業務期末賬面凈值32.19萬元，報告期內實現收益1,569.10萬元。公司應收賬款結構出現變化，1年以上應收賬款占比達27.80%，主要由於新冠疫苗相關應收賬龄逐步延長所致。公司對於1-2年的應收賬款計提比例由15%下降至10.86%，主要是因為公司預提退貨，根據扣減應付退貨款後的應收賬款餘額計提壞賬准備。公司存貨跌價准備計提合理，並無前期計提不足情況。康希諾上海臨港基地截至2023年末無減值跡象，無需計提減值。公司將繼續關注資金管理和負債結構，以支持未來的長期發展。
Conchino Bios issued an announcement on April 30, 2024, disclosing its financial position for 2023 and other related information. The Company's 2023 report showed that year-end currency capital and transactional financial assets totalled approximately $41.30 billion, and short-term and long-term borrowings totaled about $19.20 billion. In addition, the company's end-of-term derivative financial assets were $129.51 million and derivative financial liabilities were $97.32 million. The Company's main interest-bearing debt consists of short- and medium-term borrowings for day-to-day operations and R&D projects, with an average financing cost of approximately 2.92%. The company's total financial income was approximately $1.64 million, weighted by an average yield of approximately 3.3%, in line with market interest rates. Conchino also operates a foreign exchange...Show More
Conchino Bios issued an announcement on April 30, 2024, disclosing its financial position for 2023 and other related information. The Company's 2023 report showed that year-end currency capital and transactional financial assets totalled approximately $41.30 billion, and short-term and long-term borrowings totaled about $19.20 billion. In addition, the company's end-of-term derivative financial assets were $129.51 million and derivative financial liabilities were $97.32 million. The Company's main interest-bearing debt consists of short- and medium-term borrowings for day-to-day operations and R&D projects, with an average financing cost of approximately 2.92%. The company's total financial income was approximately $1.64 million, weighted by an average yield of approximately 3.3%, in line with market interest rates. Conchino also operates a foreign exchange hedging business to manage the exchange rate risk of financial assets. As of the end of the year, the net book value of hedges at the end of the year was $32.19 million and the revenue generated was $1,569.10 million during the reporting period. The Company's receivables structure has changed, accounting for 27.80% of accounts receivable over 1 year, mainly due to the gradual extension of the age of receivables related to the COVID-19 vaccine. The Company's receivables accounting ratio decreased from 15% to 10.86% for 1-2 years, mainly due to the Company's advance returns and prepared for bad accounts receivable balances after deducting the return due. THE COMPANY'S INVENTORY FALLS ARE PREPARED REASONABLY AND THERE ARE NO SHORTAGES IN ADVANCE. There are no signs of devaluation at Conchino's Shanghai base until the end of 2023, without devaluation. The Company will continue to focus on its capital management and debt structure to support long-term future development.

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more